Directory Organisation

CRT aims to maximise the potential benefit to cancer patients flowing from publicly-funded cancer research worldwide, and in so doing, be recognised as the leading oncology-focused technology transfer and development company.

Licensing portfolio includes:

A lead series of thioplatinum compounds have been developed with a bioreductive activation mechanism, which creates a tumour selective profile. These agents display a pattern of growth inhibition unlike any known antitumour agent and circumvent acquired resistance to cisplatin and other platinum drugs.